Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

4.45USD
11:37am EDT
Change (% chg)

$-0.27 (-5.72%)
Prev Close
$4.72
Open
$4.71
Day's High
$4.71
Day's Low
$4.43
Volume
21,973
Avg. Vol
50,476
52-wk High
$14.09
52-wk Low
$4.39

Chart for

About

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel... (more)

Overall

Beta: --
Market Cap(Mil.): $304.02
Shares Outstanding(Mil.): 36.63
Dividend: --
Yield (%): --

Financials

  NBRV.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -24.70 -- --
ROI: -87.80 1.58 14.38
ROE: -88.10 2.41 16.07

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

Mar 27 2018

BRIEF-Nabriva Appoints Jennifer Schranz As Chief Medical Officer

* NABRIVA THERAPEUTICS APPOINTS JENNIFER SCHRANZ, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

Mar 21 2018

BRIEF-Nabriva Therapeutics PLC Files For Mixed Shelf Of Upto $225 Million - SEC Filing

* NABRIVA THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source text (http://bit.ly/2HEW5CR) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 16 2018

BRIEF-Nabriva Therapeutics ‍had $86.9 Mln In Cash, Cash Equivalents as Of Dec 31

* NABRIVA THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

Mar 16 2018

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights

Nov 09 2017

Earnings vs. Estimates